Although the optimal treatment strategy for resectable oesophageal cancer (EC) has been a subject of debate and research for several decades, survival of EC remains poor ([@bib13]). Chemoradiation followed by surgery (trimodality treatment) is now the most common treatment strategy for EC in the United States based mainly on the results of a randomised multicentre phase 3 trial in The Netherlands (the CROSS study) ([@bib18]), whereas the combination of preoperative chemotherapy and surgery has been the mainstay of EC treatment in some parts of Europe ([@bib6]; [@bib15]). Both of these approaches are now considered standard of care. ([@bib1]) Cancer-free (R0) resection margin and pathological complete response (pathCR) are the only two factors associated with good survival of EC. The degree of pathologic response is also associated with longer survival and lower rates of recurrence ([@bib4]; [@bib19]; [@bib10]; [@bib16]). To further improve survival, targeted agents have been added but without advantage ([@bib12]; [@bib7]; [@bib14]). However, our group developed the strategy of induction chemotherapy (IC) followed by chemoradiation and then surgery. We examined the approach in a phase 2 randomised clinical trial but it did not significantly increase the pathCR rate (primary endpoint) or prolong overall survival (OS) durations; The pathCR rate in the control group was 13% (7 of 55) and 26% (14 of 54) in the induction chemotherapy group (*P*=0.094) ([@bib2]). Given these results, we did not recommend further development of the strategy but carried out an exploratory analysis to assess if there were subgroups that are likely to benefit. Herein we report on our secondary analysis of the EC patients in the phase 2 randomised trial.

Patients and methods
====================

Patient selection
-----------------

The original phase 2 study was conducted at The University of Texas MD Anderson Cancer Center from 2005 to 2011 (NCT 00525915). Patients with local-regional EC (oesophageal or gastroesophageal junction carcinoma) with histologically diagnosed as adenocarcinoma or squamous cell carcinoma who could tolerate surgery were eligible for the trial. Patients diagnosed with T1N0 disease according to endoscopic ultrasound, T4 tumours with any N stage, and M1 cancer were ineligible. Eligible patients had to have satisfactory organ function, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, age younger than 76 years, and T1N+ or T2--3 EC according to endoscopic ultrasound with any baseline N stage. After all patients provided their written informed consent to participate in the study, the multidisciplinary team evaluated and discussed their cases prior to initiating treatment. The MD Anderson Institutional Review Board approved the study protocol. The trial was monitored continuously by the institution's data and safety monitoring committee.

Therapy
-------

All qualifying patients were randomly put into one of two study arms using an in-house web-based software program that dynamically balanced the two groups according to sex, race, age, tumours histology, and baseline disease stage. All treatments were performed in the outpatient setting. Arm A consisted of chemoradiation followed by surgery, whereas Arm B consisted of IC followed by chemoradiation and then surgery ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).

Patients assigned to Arm A received 50.4 Gy of proton or photon radiation (intensity-modulated) in 28 fractions. At the same time, they received fluorouracil (250 mg m^−2^ per daily as a 24-h infusion from Monday to Friday for 5 weeks) and oxaliplatin (40 mg/ m^−2^ intravenously once a week for five doses). After recovery from the chemoradiation for 5--7 weeks, preoperative staging and surgical evaluation of the patients was performed. The surgeries consisted of minimally invasive, three-field, transhiatal, and transthoracic oesophagectomy. Surgery was selected by the operating team. Other routine preoperative investigations were performed.

Patients in Arm B received IC for up to two cycles (8 weeks) before preoperative chemoradiation. IC consisted of a 4-week cycle of 2200 mg/ m^−2^ fluorouracil infused over 48 h starting on days 1 and 15 and 100 mg/ m^−2^ oxaliplatin on days 1 and 15. This regimen was a modification of a colon cancer treatment regimen agreed upon by our team and the trial sponsor. Positron emission tomography or endoscopic evaluation of each patient was performed after one cycle of IC to evaluate their treatment responses and monitor EC progression. Patients confirmed to have no progression after the first cycle of IC proceeded to cycle 2, in which they received the same treatment as in Arm A.

Statistical analysis
--------------------

Dynamic patient randomisation was performed using the method described by Pocock and Simon ([@bib11]). Patient characteristics were tabulated overall and in both treatment arms. OS was defined as the number of years from randomisation to death or last follow-up. Survival curves were estimated using the Kaplan--Meier method ([@bib8]), and median OS durations were reported with 95% confidence intervals. Tumour length, number of SUV avid lymph nodes, baseline T stage, baseline N stage, baseline clinical stage, and tumour grade were clinically relevant tumour measures included in multivariate models used to determine the effect of treatment. Due to the small number, the well-differentiated group was combined with the moderately differentiated group, Stage I was combined with Stage II, and N3 was combined with N2. Univariate and multivariate Cox proportional hazards regression models ([@bib5]) were used to assess the associations between patient characteristics and OS. Clinically relevant tumour measures and the treatment arms were considered in the multivariate (full) model. Backward elimination was implemented until all remaining predictors had *P* values \<0.05 (reduced model). The interaction of treatment arm and categorical patient characteristics were added to the Cox proportional hazards regression models to identify patient subgroups whose tumours may respond well to IC. Survival curves were estimated using the Kaplan--Meier method and compared using log-rank tests ([@bib9]).

Univariate and multivariate logistic regression models were applied to evaluation of the relationships between patient characteristics and pathCR. Exact logistic regression was applied when a subgroup had fewer than five patients with or without a pathCR. Clinically relevant tumour measures and the treatment arms were included in the multivariate model. Backward elimination then was implemented until all remaining predictors had *P*-values \<0.05.

Recursive partitioning analysis (RPA) was applied to classification of subgroups of patients based on OS or pathCR using the clinically relevant tumour measures and treatment arms ([@bib3]; [@bib17]). The minimum number of patients in any terminal subgroup was set to 15. A two-sided log-rank test was used to assess the differences in OS among the subgroups of patients. A log-rank test was applied in each split and splitting was stopped when the *P* value for any split was \>0.05. Terminal subgroups of patients were compared pairwise using a log-rank test. If the *P*-value was \<0.20, then the two terminal subgroups in the comparison were combined.

Statistical analysis was performed using the SAS software program (version 9.3; SAS Institute, Cary, NC) except for RPA, which was performed using the R computing language. Figures were created using the Stata software program (version 13.1; StataCorp, College Station, TX, USA).

Results
=======

Patient characteristics
-----------------------

We included a total of 126 EC patients with dates of randomisation from April 2005 to May 2011 in this study. Patient characteristics are listed in [Table 1](#tbl1){ref-type="table"}. Patients were predominantly white (94%) and male (94%), with most having an Eastern Cooperative Oncology Group (ECOG) performance status of 1 (65%), type 1 adenocarcinoma of the oesophagogastric junction (AEG; 64%), an advanced baseline T stage (T3; 84%), an advanced baseline clinical stage (IIIA, IIIB, or IIIC; 60%), adenocarcinoma (97%), and poorly differentiated tumours (53%). We observed an imbalance in ECOG performance status between the two treatment arms (*P*=0.02), as patients who received IC more often had an ECOG performance status of 0 than did patients who did not undergo IC (44 *vs* 25%).

OS
--

The median follow-up duration in the EC survivors was 6.7 years (range, 3.3--9.8 years). Seventy-three (58%) patients died during the study period, leaving 53 (42%) alive at last follow-up. The median OS duration was 3.8 years (95% confidence interval, 2.6-5.8 years). The 5-year survival rate was 45% (standard error=4%) ([Figure 1A](#fig1){ref-type="fig"}). [Table 2](#tbl2){ref-type="table"} lists the OS and 5-year survival rates according to patient characteristics. OS was significantly associated with tumour length (*P*=0.03), T stage (*P*=0.02), N stage (*P*=0.04), clinical stage (*P*=0.01), and tumour grade (*P*\<0.001). After 2 years of follow-up, OS was longer for the patients who received IC, but this difference was not significant (*P*=0.13) ([Figure 1B](#fig1){ref-type="fig"}). Multivariate OS analysis results are listed in [Table 3](#tbl3){ref-type="table"}. Only tumour grade was significantly associated with OS in the full multivariate Cox proportional hazards model, demonstrating that patients with well or moderately differentiated tumours lived longer than did those with poorly differentiated tumours (hazard ratio, 0.44; *P*=0.001). Use of a reduced multivariate Cox proportional hazards model demonstrated that the effect of baseline T stage on OS became visible and that tumour grade remained significantly associated with OS. Patients with an advanced baseline T stage (*P*=0.02) or poorly differentiated tumours (*P*\<0.001) were at increased risk for death.

EC patients possibly benefiting from IC
---------------------------------------

[Table 4](#tbl4){ref-type="table"} summarises the results of Cox regression analysis of OS when we took into account the interaction between treatment arm and patient characteristics to identify differential treatment effects. We found that the baseline N stage was significantly associated with OS (*P*=0.02) in the Cox regression model of the interaction between this stage and treatment arm, although the interaction effect was not significant. Importantly, only the interaction between treatment arm and tumour grade was significantly associated with OS (*P*=0.04). Even with this interaction, the treatment arm (*P*=0.03) and tumour grade (*P*\<0.001) were both significantly associated with OS, indicating a strong differential effect of treatment on OS depending on tumour grade. [Figure 1C](#fig1){ref-type="fig"} shows a Kaplan--Meier OS curve according to treatment arm and tumour grade. The 5-year survival rate did not differ significantly according to treatment arm in the 67 patients with poorly differentiated tumours (31% *vs* 28% with and without IC, respectively) ([Table 2](#tbl2){ref-type="table"}). However, this rate did differ significantly according to treatment arm in the 59 patients with well or moderately differentiated tumours, as more of those who underwent IC than those who did not were alive at 5 years after randomisation (74% and 50%, respectively). The baseline clinical stage in patients with poorly differentiated tumours was higher than that in patients with well or moderately differentiated tumours (*P*=0.008), but other characteristics were similar in both group.

Classification of the four EC phenotypes according to clinical variables
------------------------------------------------------------------------

A tree diagram of our RPA-based classification of the study patients into four subgroups based on risk differential is presented in [Figure 2A](#fig2){ref-type="fig"}. The original tree is presented with separation according to tumour differentiation, use of IC in patients with well or moderately differentiated tumours, N stage, and baseline clinical stage in patients with poorly differentiated tumours. In the second stage, we combined different branches of patients according to risk group, resulting in four risk groups. The OS comparison among these subgroups is in the bottom of [Table 2](#tbl2){ref-type="table"}. Patients in the very high, high, moderate, and low risk subgroups had estimated 5-year survival rates of 11, 27, 48, and 74%, respectively (*P*\<0.001) ([Figure 2B](#fig2){ref-type="fig"}).

PathCR
------

Of the 109 patients known to undergo pathologic response assessment, 21 (19%) had pathCRs. No patient characteristics were significantly associated with pathCR, and we identified no splits using RPA.

Discussion
==========

Although investigators have accomplished much in both basic scientific and clinical research, EC remains an aggressive disease associated with poor OS ([@bib13]). Preoperative therapy of EC has several theoretical advantages: (1) downsizing the tumour, with increased rates of resection with no tumour within 1 mm of resection margins (R0); (2) early intervention for possible micrometastases; and (3) assessment of response to the initial treatment. On the basis of these possibilities, we previously performed a randomised phase 2 trial that unfortunately demonstrated no improvement in OS or pathCR rate with the addition of IC to chemoradiation followed by surgery ([@bib2]). Our secondary analysis of the data has produced interesting and hypothesis generating data. Initially, we thought that some patients with poorly differentiated tumours, bulky primary, or advanced baseline N stage would benefit from the addition of chemotherapy prior to chemoradiation. However, we find just the opposite that moderately or well differentiated EC patients are significant beneficiaries of IC. Unfortunately, owing to our small patient population, we cannot conclude that IC is an independent prognostic factor in this subgroup. This strategy can considerably improve outcomes in these patients, though, and it must be evaluated in prospective trials in the near future.

Moreover, we found that the four EC phenotypes classified according to clinical variables were factors for OS. The fact that we picked factors such as tumour differentiation, baseline N stage, and baseline clinical stage supports the usefulness of current EC staging methods.

In conclusion, although further study of this strategy is warranted, using IC before preoperative chemoradiation for EC, may be significantly beneficial to patients who have well or moderately differentiated tumours. However, it should not be administered to those with poorly differentiated tumours. We expect our results to become a springboard for further research and be of some help in establishing this promising strategy, which will improve outcomes and facilitate efficient use of limited medical resources in EC patients.
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![**Kaplan--Meier OS curve.** (**A**) OS for the entire patient population (**B**) OS by treatment arm. (**C**) OS by treatment arm and tumour grade. Well, well- to-moderately differentiated tumour; poor, poorly differentiated tumour.](bjc2017423f1){#fig1}

![**Four subgroups based on risk differential.** (**A**) Tree diagram of the patient subgroups based on risk differential identified using recursive partitioning analysis (RPA). (**B**) OS by Risk Groups Identified by RPA.](bjc2017423f2){#fig2}

###### Patient characteristics

                                                ***n*** **(%)**                                         
  ------------------------------------------- ------------------- ------------------ ------------------ ---------
  **Characteristic**                           (***n*****=126)**   (***n*****=63)**   (***n*****=63)**   ***P***
  Median age at presentation, years (range)       60 (27--75)        60 (29--74)        60 (27--75)       0.73
  Race                                                                                                       
   White                                           118 (94)            58 (92)            60 (95)         0.84
   Hispanic                                          6 (5)              3 (5)              3 (5)             
   Black                                             1 (1)              1 (2)              0 (0)             
   Asian                                             1 (1)              1 (2)              0 (0)             
  Sex                                                                                                        
   Female                                            9 (7)              4 (6)              4 (6)         \>0.99
   Male                                            117 (93)            59 (94)            59 (94)            
   Median tumour length, cm (IQR)                  5 (4--7)            5 (3--7)           5 (4--7)        0.87
   Median PET SUV (IQR)                        10.1 (7.0--15.4)    10.1 (7.3--16.3)   10.1 (6.7--14.3)    0.62
  Number of SUV-Avid LNs                                                                                     
   0                                                97 (77)            44 (70)            53 (84)         0.19
   1                                                14 (11)             9 (14)             5 (8)             
   \>1                                              15 (12)            10 (16)             5 (8)             
  ECOG performance status                                                                                    
   0                                                44 (35)            16 (25)            28 (44)         0.02
   1                                                82 (65)            47 (75)            35 (56)            
  Location of tumour                                                                                         
   AEG1                                             81 (64)            41 (65)            40 (63)        \>0.99
   AEG2                                             41 (33)            20 (32)            21 (33)            
   Oesophagus                                        4 (3)              2 (3)              2 (3)             
  Baseline T stage                                                                                           
   T2                                               20 (16)             9 (14)            11 (17)         0.63
   T3                                              106 (84)            54 (86)            52 (83)            
  Baseline N stage                                                                                           
   N0                                               44 (35)            22 (35)            22 (35)         0.39
   N1                                               53 (42)            23 (37)            30 (48)            
   N2                                               27 (21)            17 (27)            10 (16)            
   N3                                                2 (2)              1 (2)              1 (2)             
  Baseline clinical stage                                                                                    
   IB                                                7 (6)              4 (6)              3 (5)          0.70
   IIA                                               5 (4)              1 (2)              4 (6)             
   IIB                                              38 (30)            19 (30)            19 (30)            
   IIIA                                             49 (39)            23 (37)            26 (41)            
   IIIB                                             25 (20)            15 (24)            10 (16)            
   IIIC                                              2 (2)              1 (2)              1 (2)             
  Tumour histology                                                                                           
   Adenocarcinoma                                  122 (97)            61 (97)            61 (97)        \>0.99
   Squamous cell carcinoma                           4 (3)              2 (3)              2 (3)             
  Tumour grade                                                                                               
   G1 (well differentiated)                          1 (1)              0 (0)              1 (2)          0.72
   G2 (moderately differentiated)                   58 (46)            28 (44)            30 (48)            
   G3 (poorly differentiated)                       67 (53)            35 (56)            32 (51)            

Abbreviations: IQR= interquartile range; LNs=lymph nodes; PET=positron emission tomography; SUV=standard uptake value.

###### OS and 5-year survival rate according to patient characteristics

  **Characteristic**                                       **Number of deaths (*****n*****=73)**   **5-year survival rate (SE)**[a](#t2-fn2){ref-type="fn"}   ***P***
  ------------------------------------------------------- --------------------------------------- ---------------------------------------------------------- ---------
  Age at presentation, years[b](#t2-fn3){ref-type="fn"}                                                                                                        0.710
   \<60                                                                     34                                             48% (6%)                               
   ⩾60                                                                      39                                             42% (6%)                               
  Tumour length, cm[b](#t2-fn3){ref-type="fn"}                                                                                                                 0.030
   \<5                                                                      25                                             54% (7%)                               
   ⩾5                                                                       48                                             39% (6%)                               
  PET SUV[b](#t2-fn3){ref-type="fn"}                                                                                                                           0.640
   \<10                                                                     32                                             49% (7%)                               
   ⩾10                                                                      41                                             41% (6%)                               
  Number of SUV-Avid LNs                                                                                                                                       0.210
   0                                                                        53                                             49% (5%)                               
   ⩾1                                                                       20                                             31% (9%)                               
  ECOG performance status                                                                                                                                      0.640
   0                                                                        25                                             47% (8%)                               
   1                                                                        48                                             44% (6%)                               
  Location of tumour                                                                                                                                           0.650
   Oesophagus/AEG 1                                                         50                                             44% (5%)                               
   AEG 2                                                                    23                                             45% (8%)                               
  Baseline T stage                                                                                                                                             0.020
   T2                                                                        6                                            75% (10%)                               
   T3                                                                       67                                             39% (5%)                               
  Baseline N stage                                                                                                                                             0.040
   N0                                                                       19                                             59% (7%)                               
   N1                                                                       33                                             43% (7%)                               
   N2/N3                                                                    21                                             28% (8%)                               
  Baseline clinical stage                                                                                                                                      0.010
   I/II                                                                     21                                             60% (7%)                               
   III                                                                      52                                             35% (6%)                               
  Tumour grade                                                                                                                                                \<0.001
   Poorly differentiated                                                    48                                             29% (6%)                               
   Well-Moderately differentiated                                           25                                             62% (6%)                               
  Treatment Arm                                                                                                                                                0.130
   With IC                                                                  31                                             52% (6%)                               
   Without IC                                                               42                                             38% (6%)                               
  Treatment arm/tumour grade[c](#t2-fn4){ref-type="fn"}                                                                                                        0.001
   With IC/ well-moderately differentiated                                   9                                             74% (8%)                               
   Without IC/ well-moderately differentiated                               16                                             50% (9%)                               
   With IC/poorly differentiated                                            22                                             31% (8%)                               
   Without IC/poorly differentiated                                         26                                             28% (8%)                               
  RPA risk group[d](#t2-fn5){ref-type="fn"}                                                                                                                   \<0.001
   Low                                                                       9                                             74% (8%)                               
   Moderate                                                                 28                                             48% (7%)                               
   High                                                                     19                                             27% (9%)                               
   Very high                                                                17                                             11% (8%)                               

Abbreviations: LNs=lymph nodes; PET=positron emission tomography; SE=standard error; SUV=standard uptake value.

Entire study population: 45% (4%).

*P*-values were calculated based on continuous variables for age at presentation at MD Anderson, length of tumour, and positron emission tomography standard uptake value.

OS differed significantly according to treatment arm among patients with well/moderately differentiated tumours (*P*=0.02) but not among patients with poorly differentiated tumours (*P*=0.63).

Low risk: well/moderately differentiated tumours with IC; moderate risk: well/moderately differentiated tumours without IC or poorly differentiated tumours, N0/N1 tumours, and stage I/II disease; high risk: poorly differentiated tumours, N0/N1 tumours, and stage III disease; very high risk: poorly differentiated tumours and N2/N3 tumours.

###### Multivariate Cox proportional hazards models of OS

                                                                             **Full model**    **Reduced model**                             
  -------------------------------------------------------------------------- ---------------- ------------------- ------- ------ ----------- ---------
  Length of tumour                                                           1.02                 0.91--1.14      0.760                       
  Number of SUV-Avid LNs (≥1 *vs* 0)                                         1.16                 0.66--2.04      0.600                       
  Baseline T Stage (T3 *vs* T2)                                              2.13                 0.71--6.35      0.180   2.70   1.17-6.22   0.020
  Baseline N stage                                                                                                                            
   N1 *vs* N0                                                                1.07                 0.19--6.08      0.940                       
   N2/N3 *vs* N0                                                             1.39                 0.22--8.74      0.720                       
  Baseline Stage (III *vs* I/II)                                             1.21                 0.20--7.33      0.840                       
  Tumour Grade (Well/Moderately Differentiated *vs* Poorly Differentiated)   0.44                 0.26--0.72      0.001   0.41   0.25-0.67   \<0.001
  Treatment Arm (With IC *vs* Without IC)                                    0.85                 0.53--1.36      0.490                       

Abbreviations: CI=confidence interval; HR=hazard ratio; LNs=lymph nodes; SUV=standard uptake value.

###### Cox Regression Model of OS with treatment interaction

  **Variable**              **Treatment** ***P*** **value**   **Variable** ***P*** **value**   **Interaction** ***P*** **value**
  ------------------------- --------------------------------- -------------------------------- -----------------------------------
  Number of SUV-avid LNs    0.14                              0.860                            0.33
  ECOG performance status   0.16                              0.900                            0.68
  Tumour location           0.51                              0.290                            0.30
  Baseline T stage          0.13                              0.150                            0.75
  Baseline N stage          0.38                              0.020                            0.17
  Baseline clinical Stage   0.27                              0.070                            0.86
  Tumour grade              0.03                              \<0.001                          0.04

Abbreviations: LNs=lymph nodes; SUV=standard uptake value.
